Imatinib
- PDF / 141,433 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 41 Downloads / 179 Views
1
S
Secondary malignancies: 7 case reports Four men and three women, aged 21–69 years, developed secondary malignancies while receiving imatinib for either chronic myeloid leukaemia or GI stromal tumour*. The patients, who had been receiving imatinib 400mg [frequencies and routes not stated] for between 14 months and 7 years, were diagnosed with secondary malignancies. One patient developed diffuse large B cell lymphoma (DLBCL), while the remaining six patients had solid tumours. The solid tumours were a dermatofibroma, basal cell skin cancer, gastric adenocarcinoma, small-cell lung cancer, colon cancer and thyroid papillary cancer. Two patients received chemotherapy for lung and colon cancer, respectively. One of these patients switched to nilotinib due to imatinib intolerance, while the other received dasatinib due to imatinib resistance. One patient received radioactive iodine therapy for thyroid cancer, and another patient with dermatofibroma underwent surgery. At last follow-up, the patients with DLBCL and skin cancer were in remission. Author comment: "We report eight patients who developed secondary neoplasms during imatinib treatment." * The details of the eighth patient have been previously published. Duman BB, et al. Secondary malignancy after imatinib therapy: Eight cases and review of the literature. Leukemia and Lymphoma 53: 1706-1708, No. 9, Sep 2012. Available from: URL: http://dx.doi.org/10.3109/10428194.2012.666545 803078601 Turkey
0114-9954/10/1423-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 13 Oct 2012 No. 1423
